文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

肠道微生物组中丁酸合成遗传能力降低的决定因素在克罗恩病和溃疡性结肠炎中的作用。

Determinants of Reduced Genetic Capacity for Butyrate Synthesis by the Gut Microbiome in Crohn's Disease and Ulcerative Colitis.

机构信息

APC Microbiome Institute, University College Cork, Cork, Ireland.

School of Microbiology, University College Cork, Cork, Ireland.

出版信息

J Crohns Colitis. 2018 Jan 24;12(2):204-216. doi: 10.1093/ecco-jcc/jjx137.


DOI:10.1093/ecco-jcc/jjx137
PMID:29373727
Abstract

BACKGROUND AND AIMS: Alterations in short chain fatty acid metabolism, particularly butyrate, have been reported in inflammatory bowel disease, but results have been conflicting because of small study numbers and failure to distinguish disease type, activity or other variables such as diet. We performed a comparative assessment of the capacity of the microbiota for butyrate synthesis, by quantifying butyryl-CoA:acetate CoA-transferase [BCoAT] gene content in stool from patients with Crohn's disease [CD; n = 71], ulcerative colitis [UC; n = 58] and controls [n = 75], and determined whether it was related to active vs inactive inflammation, microbial diversity, and composition and/or dietary habits. METHODS: BCoAT gene content was quantified by quantitative polymerase chain reaction [qPCR]. Disease activity was assessed clinically and faecal calprotectin concentration measured. Microbial composition was determined by sequencing 16S rRNA gene. Dietary data were collected using an established food frequency questionnaire. RESULTS: Reduced butyrate-synthetic capacity was found in patients with active and inactive CD [p < 0.001 and p < 0.01, respectively], but only in active UC [p < 0.05]. In CD, low BCoAT gene content was associated with ileal location, stenotic behaviour, increased inflammation, lower microbial diversity, greater microbiota compositional change, and decreased butyrogenic taxa. Reduced BCoAT gene content in patients with CD was linked with a different regimen characterised by lower dietary fibre. CONCLUSIONS: Reduced butyrate-synthetic capacity of the microbiota is more evident in CD than UC and may relate to reduced fibre intake. The results suggest that simple replacement of butyrate per se may be therapeutically inadequate, whereas manipulation of microbial synthesis, perhaps by dietary means, may be more appropriate.

摘要

背景和目的:短链脂肪酸代谢的改变,特别是丁酸盐,在炎症性肠病中已有报道,但由于研究数量较少且未能区分疾病类型、活动度或其他变量(如饮食),结果存在冲突。我们通过定量检测粪便中丁酰辅酶 A:乙酰辅酶 A 转移酶(BCoAT)基因含量,对微生物合成丁酸盐的能力进行了比较评估,该基因含量来自克罗恩病(CD;n = 71)、溃疡性结肠炎(UC;n = 58)和对照组(n = 75)患者。并确定其是否与活跃与不活跃的炎症、微生物多样性、组成和/或饮食习惯有关。

方法:通过定量聚合酶链反应(qPCR)定量检测 BCoAT 基因含量。临床评估疾病活动度,测定粪便钙卫蛋白浓度。通过 16S rRNA 基因测序确定微生物组成。使用既定的食物频率问卷收集饮食数据。

结果:发现活跃和不活跃的 CD 患者的丁酸盐合成能力降低(p < 0.001 和 p < 0.01),但仅在活跃的 UC 患者中降低(p < 0.05)。在 CD 中,低 BCoAT 基因含量与回肠部位、狭窄行为、炎症增加、微生物多样性降低、微生物组成变化更大以及产丁酸菌减少有关。CD 患者 BCoAT 基因含量降低与膳食纤维摄入较低的不同饮食方案有关。

结论:与 UC 相比,CD 患者的微生物丁酸盐合成能力降低更为明显,可能与膳食纤维摄入减少有关。结果表明,简单地替代丁酸盐本身可能在治疗上是不够的,而通过饮食等方式对微生物合成的干预可能更为恰当。

相似文献

[1]
Determinants of Reduced Genetic Capacity for Butyrate Synthesis by the Gut Microbiome in Crohn's Disease and Ulcerative Colitis.

J Crohns Colitis. 2018-1-24

[2]
Alterations in the relative abundance of correlate with changes in fecal calprotectin in patients with ileal Crohn's disease: a longitudinal study.

Scand J Gastroenterol. 2019-5

[3]
Intestinal Taxa Abundance and Diversity in Inflammatory Bowel Disease Patients: An Analysis including Covariates and Confounders.

Nutrients. 2022-1-8

[4]
A microbial signature for Crohn's disease.

Gut. 2017-5

[5]
A Diversified Dietary Pattern Is Associated With a Balanced Gut Microbial Composition of Faecalibacterium and Escherichia/Shigella in Patients With Crohn's Disease in Remission.

J Crohns Colitis. 2020-11-7

[6]
Fecal microbial dysbiosis in Chinese patients with inflammatory bowel disease.

World J Gastroenterol. 2018-4-7

[7]
IL23R-Protective Coding Variant Promotes Beneficial Bacteria and Diversity in the Ileal Microbiome in Healthy Individuals Without Inflammatory Bowel Disease.

J Crohns Colitis. 2019-3-30

[8]
Analysis of Flagellin-Specific Adaptive Immunity Reveals Links to Dysbiosis in Patients With Inflammatory Bowel Disease.

Cell Mol Gastroenterol Hepatol. 2020

[9]
Characteristics of Faecal Microbiota in Paediatric Crohn's Disease and Their Dynamic Changes During Infliximab Therapy.

J Crohns Colitis. 2018-2-28

[10]
Inulin-type fructans improve active ulcerative colitis associated with microbiota changes and increased short-chain fatty acids levels.

Gut Microbes. 2018-11-5

引用本文的文献

[1]
Quantitative Alterations in Short-Chain Fatty Acids in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.

Biomolecules. 2025-7-15

[2]
The Impact of Imidacloprid in Dietary Residues on Intestinal Damage and the Increased Risk of Enterotoxigenic Infection.

Foods. 2025-6-17

[3]
Gut microbiota-derived short-chain fatty acids and their role in human health and disease.

Nat Rev Microbiol. 2025-5-13

[4]
genetically modified for purine nucleobase release promotes butyrate generation and colonic wound healing during DSS insult.

Gut Microbes. 2025-12

[5]
The Combination of JLCC513 and Ginseng Soluble Dietary Fiber Attenuates Ulcerative Colitis by Modulating the LPS/TLR4/NF-κB Pathway and Gut Microbiota.

J Microbiol Biotechnol. 2024-6-28

[6]
Gastrointestinal microbiota-directed nutritional and therapeutic interventions for inflammatory bowel disease: opportunities and challenges.

Gastroenterol Rep (Oxf). 2024-4-27

[7]
Swapping White for High-Fibre Bread Increases Faecal Abundance of Short-Chain Fatty Acid-Producing Bacteria and Microbiome Diversity: A Randomized, Controlled, Decentralized Trial.

Nutrients. 2024-3-28

[8]
The effect of oral butyrate on colonic short-chain fatty acid transporters and receptors depends on microbial status.

Front Pharmacol. 2024-3-26

[9]
Gut Microbiota Metabolites: Unveiling Their Role in Inflammatory Bowel Diseases and Fibrosis.

Pharmaceuticals (Basel). 2024-3-7

[10]
Harnessing and delivering microbial metabolites as therapeutics via advanced pharmaceutical approaches.

Pharmacol Ther. 2024-4

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索